Sabate M, Cequier A, Iniguez A, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial[J]. Lancet, 2012, 380(9852): 1482-1490. [2]Kedhi E, Gomes M E, Lagerqvist B, et al. Clinical impact of second-generation everolimus-eluting stent compared with first-generation drug-eluting stents in diabetes mellitus patients: insights from a nationwide coronary intervention register[J]. JACC Cardiovasc Interv, 2012, 5(11): 1141- 1149. [3]Byrne R A, Sarafoff N, Kastrati A, et al. Drug-eluting stents in percutaneous coronary intervention: a benefit-risk assessment[J]. Drug Saf, 2009, 32(9): 749-770. [4]Gorla R, Loffi M, Verna E, et al. Safety and efficacy of first-generation and second-generation drug-eluting stents in the setting of acute coronary syndromes[J]. J Cardiovasc Med (Hagerstown), 2014, 15(7): 532-542. [5]Cutlip D E, Windecker S, Mehran R, et al. Clinical end point in coronary stent trials: a case for standardized definitions[J]. Circulation, 2007, 115(17): 2344-2251. [6]Kip K E, Faxon D P, Detre K M, et al. Coronary angioplasty in diabetic patients. The National Heart, Lung and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry[J]. Circulation, 1996, 94(8): 1818-1825. [7]Sato T, Ono T, Morimoto Y, et al. Five-year clinical outcomes after implantation of sirolimus-eluting stents in patients with and without diabetes mellitus[J]. Cardiovasc Interv ？Ther？, 2012, 27(3): 189-195. [8]Stone G W, Ellis S G, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial[J]. JAMA, 2005, 294(10): 1215-1223. [9]Mathew V, Gersh B J, Williams B A, et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial[J]. Circulation, 2004, 109(4): 476-480. [10]Garg S, Serruys P. Biodegradable stents and non-biodegradable stents[J]. Minerva Cardioangiol, 2009, 57(5): 537-565. [11]周妍卉, 郝亚荣. 可降解涂层与永久涂层药物洗脱支架治疗冠状动脉粥样硬化性心脏病合并糖尿病患者的近期疗效[J]. 新乡医学院学报, 2013, 30(11): 906-908.
[2]
牟海刚,古平.莱姆病伴直立性低血压误诊为糖尿病心血管自主神经病1例[J].第三军医大学学报,2012,34(15):1542. [2]周厚地,童强,段炼,等.胃大部切除术致糖尿病患者反复低血糖1例[J].第三军医大学学报,2012,34(17):1753. [3]吴艳,王毅,曾绍凡,等.老年2型糖尿病瘦素、骨密度变化及相关因素的研究[J].第三军医大学学报,2007,29(22):2188. WU Yan,WANG Yi,ZENG Shao-fan,et al.Bone density, leptin level and other related factors in elder patients with type 2 diabetes[J].J Third Mil Med Univ,2007,29(09):2188. [4]李志勤.饮食护理干预对老年糖尿病患者血糖和糖化血红蛋白水平的影响[J].第三军医大学学报,2012,34(20):2130. [5]徐灵莉,邓本敏,唐玲,等.护理风险管理能有效提高糖尿病合并恶性肿瘤患者的化疗疗效[J].第三军医大学学报,2013,35(04):351. Xu Lingli,Deng Benmin,Tang Ling,et al.Risk management of nursing improves chemotherapy efficiency for diabetic patients with malignant tumor[J].J Third Mil Med Univ,2013,35(09):351. [6]魏平.糖尿病治疗的新趋势及相关热点追踪[J].第三军医大学学报,2012,34(23):2435. [7]李明秀,王建,樊荣,等.癌症合并糖尿病患者住院期间的营养治疗[J].第三军医大学学报,2007,29(21):2079. [8]高原,肖谦,赵柯湘,等.替米沙坦对糖尿病大鼠认知功能的保护作用[J].第三军医大学学报,2007,29(15):1514. GAO Yuan,XIAO Qian,ZHAO Ke-Xiang,et al.The study of the protection of telmisartan on the cognitive function in diabetic rats[J].J Third Mil Med Univ,2007,29(09):1514. [9]范伟,杨妤欣,陈隽,等.糖尿病大鼠早期骨微结构改变及其BMP-2基因的表达[J].第三军医大学学报,2007,29(11):1053. FAN Wei,YANG Yu-xin,CHEN Juan,et al.Bone microstructure changes and bone BMP-2 expression in rats at early period of diabetes[J].J Third Mil Med Univ,2007,29(09):1053. [10]杨光玉,卿尚兰,陈英.糖尿病患者根管治疗中疼痛有关因素的临床研究[J].第三军医大学学报,2007,29(10):982. YANG Guang-yu,QING Shang-lan,CHEN Ying.Correlation of diabetes mellitus and endodontic interappointment pain[J].J Third Mil Med Univ,2007,29(09):982.
